News & PR


Below you will find news about our company and logos and pictures for download.

If you have questions or other inquiries regarding press & media please contact us via cerff@bevsnez.pbz  



Orifarm Group announces signing of large multi-million Euro acquisition from Takeda

Orifarm Group (“Orifarm”), one of the leading pharmaceutical companies in the Nordic countries, has entered into an agreement to purchase a portfolio of select over-the-counter (OTC) and prescription pharmaceutical products sold in Europe from Takeda Pharmaceutical Company Limited (“Takeda”) for a purchase price of up to €615 million. Orifarm has acquired the rights for approximately 110 pharmaceuticals as well as 2 production sites.

Read the press release here


Orifarm Group A/S with new record-breaking result

The Odense based pharmaceutical company Orifarm is presenting a new record-breaking annual report with the highest turnover and earnings in the company’s 25-year history.

Read the press release here



Orifarm presents best result ever

For Orifarm, 2018 was a fantastic year. In fact, the best in the company's nearly 25-year history. Every day, the employees work hard to challenge the pharmaceutical market to provide cheaper pharmaceuticals to millions of consumers in Europe. And the employees do it well. In 2018, Orifarm Group sold more than 25 million products - or approx. 7% more products than in 2017, and this has resulted in record turnover and earnings.



Record-breaking result from Orifarm Group

Orifarm Group manages to provide cheaper pharmaceuticals to millions of consumers in Europe while earning money to invest in future activities. Despite fierce competition, Orifarm closes its fiscal year 2017 with an annual result showing 10 percent growth in net turnover and the second best earnings in the history of the company.


Continuous growth for Orifarm Group

Orifarm Group once again closes its fiscal year with a great result. Despite the challenging market conditions in 2016, Orifarm Group succeeded continuing the growth the company has experienced in recent years.


Progress continues at Orifarm

Orifarm Group continues its progress of recent years. The annual result shows growth in both top and bottom line, and this trend is partly due to successful acquisitions and significant growth in the sales of generic pharmaceuticals.


Orifarm Generics has acquired Alternova, Viminco and Pilum Pharma

Orifarm Generics, subsidiary company of Orifarm Group, has acquired Growth House Holding including the companies Alternova, Viminco and Pilum Pharma, which develop, manufacture and sell generic pharmaceutical products in the Nordic countries.


Annual Report 2014: Progress continues for Orifarm

Denmark's biggest supplier of pharmaceuticals, Orifarm Group, continues its positive development. The annual results for 2014 shows an increase in revenue and an improved operating result, not least due to a significant improvement in the business area of generic medications.


Change of ERP systems by 1st of March: Pharma Westen is now Orifarm

From 1st March 2014 Pharma Westen operates under the name of Orifarm GmbH. As part of the renaming, the ERP-systems were changed. Pharmaceuticals can now be ordered under the new name Orifarm (abbreviation: ORI). 

Press Material

The imprint of the pictures is free of charge - please mention the source "Orifarm A/S". The pictures of Orifarm's management and founding couple are available on request. Just contact us via cerff@bevsnez.pbz